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INCREASED SENSITIVITY OF TWO-STEP CYTOMEGALOVIRUS PCR
ANALYSIS ON PERIPHERAL BLOOD LEUKOCYTES PERMITS DETAILED
ANALYSIS OF REACTIVATION AND IMMUNE RECONSTITUTION
Vana, M.L., Formankova, D., Cha, S., Sharma, A., Potena, L.,
Brown, J.M., Mocarski, E.S. Stanford University School of Medicine,
Stanford, CA.
Although current methods to detect human cytomegalovirus
(CMV) infection following hematopoietic cell transplantation
(HCT) have adequate sensitivity to guide preemptive treatment,
we chose to monitor CMV with a more sensitive PCR approach to
try to better understand the degree and timing of reactivation. The
purpose of this study was to compare the occurrence of CMV
reactivation during the ﬁrst 100 days post HCT in patients receiv-
ing a non-myeloablative (NMA) or myeloablative (MA) regimen
prior to allogeneic HCT. We analyzed reactivation in 98 consec-
utive patients undergoing HCT (MA  48 and NMA  50) with
the COBAS AMPLICOR™ quantitative PCR on plasma (n  98)
and a more sensitive two-step PCR (qualitative nested PCR and
quantitative real-time PCR) on peripheral blood leukocytes (PBL,
n  77). The estimated cumulative incidence of reactivation was
similar in both patient groups using either AMPLICOR™ (63%
NMA, 68% MA) or nested PCR (80% NMA, 100% MA). How-
ever, reactivation was detected earlier in the NMA group com-
pared to the MA group using either method (AMPLICOR™ P 
.012, nested PCR P  .002). Of the 77 patients followed by both
AMPLICOR™ and nested PCR, 9 patients in each of the NMA
(21%) and MA (26%) groups had levels of CMV DNA detectable
with nested PCR but not with AMPLICOR™. When levels of
viral DNA were quantiﬁed using real-time PCR, we found that the
CMV copy number was lower in the NMA group compared to the
MA group at the ﬁrst positive PCR result (P  .038) and at the
peak viral load (P  .02), suggesting NMA patients are better able
to control CMV early post-transplant. However, more NMA pa-
tients had late CMV disease. We also compared the timing of
CMV reactivation in relation to acute graft vs. host disease
(aGvHD) in the NMA and MA groups, as differences between
these patient groups are unclear. When using nested PCR we
found that all of the NMA patients (n  5 of 5, 100%) reactivated
before aGvHD, in contrast to the MA group where few patients
(n  2 of 10, 20%) reactivated before aGvHD (P  .037). There
was a similar trend with AMPLICOR™, as almost half of the
NMA patients (n 3 of 7, 43%) and none of the MA patients (n
0 of 10) reactivated before aGvHD. These data suggest that PCR
on PBL may be an effective way to further understand the timing
of CMV reactivation in relation to aGvHD in the NMA and MA
groups. In addition, detection of CMV with PCR on PBL may be
a sensitive method with which to monitor immune reconstitution
after HCT.
76
UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION USING TBI/
FLAG CONDITIONING REGIMEN FOR ADVANCED HEMATOLOGICAL MA-
LIGNANCIES
Okada, M.1, Misawa, M.1, Kai, S.2, Nakajima, T.1, Nomura, K.1,
Okikawa, Y.1, Satake, A.1, Itoi, H.1, Takatsuka, H.1, Itsukuma, T.3,
Nishioka, K.3, Fujimori, Y.3, Ogawa, H.1 1Division of Hematology,
Department of Internal Medicine; 2Division of Blood Transfusion; 3Lab-
oratory of Cell Transplantation, Institute for Advanced Medical Sciences,
Nishinomiya, Hyogo, Japan.
A combined chemotherapy using ﬂudarabine (Flu), cytosine ar-
abinoside and granulocyte colony-stimulating factor (FLAG) has
been reported to be effective in the treatment of relapsed or
refractory leukemias. Rationale for FLAG therapy is (i) Flu infu-
sion before Ara-C increases the accumulation of the active metab-
olite ara-C triphosphate (ara-CTP) (ii) G-CSF may sensitize leu-
kemic blasts to S-phase speciﬁc Ara-C by recruiting quiescent cells
into cell cycle and increasing Ara-C phosphorylation. Flu is also
highly immunosuppressive agent and frequently used in prepara-
tive regimen for stem cell transplantation. We here report thirty-
two patients with advanced hematological malignancies who un-
derwent cord blood transplantation (CBT) with a conditioning
regimen composed of 1200 cGy total body irradiation (TBI) and
FLAG therapy (TBI/ FLAG). Graft-versus-host disease (GVHD)
prophylaxis was FK506 or cyclosporin A and/or methotrexate. The
cumulative incidence of sustained donor engraftment was 91%.
The median number of days to an absolute neutrophil count of
500/ml was 22 (range, 19-31 days). The median time to an un-
transfused platelet count of 50000/ml was 46 (range, 21-208 days).
The incidence of grades II-IV acute GVHD was 67%. Eleven
patients were alive at a median follow-up of 22 months (range, 5-58
months). Three year overall survival and disease-free survival rates
were 34 and 26%, respectively. The result suggests that this novel
regimen is well tolerable and offers rapid donor cell engraftment.
Thus, this study demonstrated the feasibility of FLAG/TBI as a
conditioning regimen in CBT in advanced hematological malig-
nancies.
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DEPLETION OF RECIPIENT NK CELLS SIGNIFICANTLY INCREASES EN-
GRAFTMENT OF HAPLO-MATCHED HIGHLY PURIFIED HEMATOPOIETIC
STEM CELLS
Smith-Berdan, S.K., Gille, D., Fong, T., Christensen, J. Cellerant
Therapeutics, San Carlos, CA.
Hematopoietic stem cell transplantation has been shown to be a
potential curative treatment for malignant and nonmalignant he-
matopoietic disorders. However, many patients lack an HLA iden-
tical matched donor, and haplo-matched transplanted patients are
at risk of developing acute and chronic graft versus host disease
(GvHD). Preparations of puriﬁed hematopoietic stem cells (HSC)
depleted of T cells greatly decrease the risk of GvHD. However,
transplantation of allogeneic haplo or completely mismatched pu-
riﬁed HSC results in greater resistance to engraftment compared
to whole bone marrow. An earlier study demonstrated that barriers
to engraftment of allogeneic HSC may be decreased by increasing
the stem cell dose (Uchida et al., 1998); however, the mechanism of
inhibition of engraftment of puriﬁed HSC was not shown. Our
study evaluated hematopoietic recovery kinetics (WBC, RBC, and
platelets) and long-term functional immune restoration of highly
puriﬁed mouse KTLS HSC in syngeneic, MHC-matched unre-
lated (MUD) and haplo-identical transplantation models. Mice
transplanted with haplo-identical HSC exhibited slower recovery
kinetics, decreased levels of donor chimerism and survival at all
HSC doses tested as compared to syngeneic or MUD HSC. Pre-
treatment of recipients with antibody to clear residual NK cells
improved recovery kinetics, donor chimerism and survival of
haplo-identical HSC transplants equal to levels observed with
syngeneic HSC transplants. Analysis of transplanted mice revealed
no quantitative differences of donor B and T lymphoid, myeloid,
or NK cells in the bone marrow, spleen, thymus, lymph nodes and
peripheral blood. Progenitor compartments and B and T lymphoid
maturation pathways appeared normal. Immunization of haplo-
identical HSC transplanted mice with ova, elicited a speciﬁc T-
mediated B cell response in all three transplant models. These data
illustrate that depletion of residual host NK cell activity in prep-
aration for puriﬁed haplo-identical HSC transplantation results in
rapid early immune recovery and a quantitative and qualitative
restoration of the adaptive immune response equivalent to fully
matched HSC. Our studies suggest the potential clinical use of
puriﬁed haplo-identical HSC could be safely broadened by deple-
tion of host NK cells in transplant patients without a matched
related donor.
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GENOTYPING KILLER IMMUNOGLOBULIN-LIKE RECEPTORS USING
MALDI-TOF MASS SPECTROMETRY FOR STEM CELL TRANSPLANT DO-
NOR SELECTION
Trachtenberg, E.A.1, Nichols, R.J.1, Boal, H.E.1, Maiers, M.2,
Houtchens, K.A.1 1C.H.O.R.I., Oakland, CA; 2N.M.D.P., Minneapolis,
MN.
The highly polymorphic receptors known as killer immunoglob-
ulin-like receptors (KIR) are one of several families of receptors
involved in regulating the activity of natural killer (NK) cells, a
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component of the innate immune system specialized to kill host
cells that have become transformed or virally infected [1]. KIR are
diverse in terms of the number, type, and combination of genes
present in individuals, and display extensive polymorphism at the
nucleotide level. The ligands for NK receptors include the poly-
morphic human leukocyte antigen (HLA) class I cell surface mol-
ecules. Recent evidence suggests that interactions between an in-
dividual’s KIR molecular proﬁle and HLA class I ligands may play
an important role in stem cell transplant outcome; NK activation
may be of beneﬁt in hematopoietic transplants as donor NK cells
in a KIR/HLA mismatched transplant have shown the ability to
attack host leukemias and reduce graft versus host disease and graft
rejection [2,3,5]. Thus assessment of KIR genotypes may become
part of the donor selection process. As part of a larger study to
analyze the role of donor and recipient KIR and HLA ligand
proﬁles in stem cell transplantation, we are developing a novel,
high-throughput single nucleotide polymorphism (SNP)-based
KIR genotyping methodology. In this assay, the masses generated
in a SNP-based primer extension reaction are analyzed on a ma-
trix-assisted laser desorption/ionization time-of-ﬂight mass spec-
trometer (MALDI-TOF). The method uses 384-well microarray
chips, and is both highly accurate and rapid [4]. We present data
using this novel typing method to demonstrate that the method is
capable of accurately deﬁning KIR genotypes in a panel of 100
donor recipient pairs from the NMDP. We are collaborating with
the NMDP on an analysis of the KIR/HLA proﬁles of this panel
and their relationship to hematopoietic transplant outcomes.
1. Lanier LL. Curr Opin Immunol. 2003;15:308-314.
2. Ruggeri L, Capanni M, Urbani E, et al. Science. 2002;295:
2097-2100.
3. Gagne K, Brizard G, Gueglio B, et al. Hum Immunol. 2002;
63:271-280.
4. New MassARRAY Homogenous MassEXTEND (hME) As-
say. Sequenom. http://www.sequenom.com.
5. Shilling HG, McQueen KL, Cheng NW, Shizuru JA, Negrin
RS, Parham P. Blood. 2003;101:3730-3740.
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EVALUATION OF UNRELATED DONOR SEARCH STRATEGY PROFICIEN-
CIES
Davis, J.W., Buck, K., Dorr, L., Kempenich, J., Beduhn, E., Maus, T.,
Setterholm, M., Chitphakdithai, P. National Marrow Donor Program,
Minneapolis, MN.
A study completed by the National Marrow Donor Program
(NMDP) evaluated search strategy proﬁciencies of U.S. transplant
centers in selecting matched unrelated donors (MUD). The three
objectives were: 1) to assess the quality of transplant center search
practices, 2) to evaluate effectiveness of NMDP services and 3) to
identify areas where further education is needed. Within the one
year study, the ﬁrst 5 new MUD searches were evaluated for each
transplant center. For centers with lower transplant activity, all
MUD searches were evaluated (15% had 4 searches). Search
indicators scored were: 1) patient HLA typing—loci and level of
resolution, 2) search strategy and 3) number of donors selected.
Scores were averaged and centers were placed into prospectively
determined groups. Center speciﬁc factors in the statistical evalu-
ation were: 1) use of NMDP HLA expert consultations, 2) receipt
of preliminary search reviews, 3) having Certiﬁed Hematopoietic
Transplant Coordinator (CHTC) staff, and 4) volume of unrelated
donor transplants per year. The study included 484 MUD searches
for 106 transplant centers. The cumulative scores separated
centers into three proﬁciency categories of high (56% of the
centers), medium (29%) and low (15%). Multivariate logistic
regression was performed to control for bias. Since the response
variable “proﬁciency category” is ordinal, a proportional odds
model was used, with the probability of having higher ranking
being modeled. After adjusting for other factors, expert HLA
consultations (P  .007) and CHTC (P  .03) signiﬁcantly
affected the proﬁciency ranking (Table 1). Centers with at least
one CHTC staff or centers using HLA expert consultations
tended to have higher rankings. Unrelated transplant volume
and receipt of NMDP preliminary search reviews did not sig-
niﬁcantly affect the performance ratings (Table 1). The majority
of the transplant centers scored in the highest category demon-
strating optimal practices. The transplant centers in the lowest
category tended to select too few donors and use less than
optimal resolution for recipient HLA typing, indicating a need
for targeted education in these areas. Two NMDP programs,
Certiﬁed Hematopoietic Transplant Coordinator and HLA
search consultation, were signiﬁcantly associated with optimal
search practices.
Table 1. Logistic Regression Result for TC Proﬁciency Rankings
Factor
Odds
Ratio
95%
CI
P
Value
Favorable
Characteristic
Center volume Not significant
Low 1  
Medium and high 1.85 (0.82, 4.15) .10
HLA consultant used? Used HLA consultant
No 1  
Yes 3.96 (1.45, 10.86) .007
CHTC staff Had CHTC staff
No 1  
Yes 2.46 (1.08, 5.57) .03
Preliminary reviews Not significant
No 1  
Yes 1.47 (0.67, 3.26) .30
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TREATMENT FOR ACUTE MYELOGENOUS LEUKEMIA BY LOW DOSE
TOTAL BODY IRRADIATION (TBI) BASED CONDITIONING AND HEMA-
TOPOIETIC CELL TRANSPLANTATION FROM RELATED AND UNRE-
LATED DONORS
Franke, G.N.1, Hegenbart, U.1, Niederwieser, D.1,
Sandmaier, B.M.2,3, Maris, M.B.2,3, Shizuru, J.A.4, Stuart, M.4,
Greinix, H.5, Cordonnier, C.6, Rio, B.7, Gratwohl, A.8, Lange, T.1,
Poenisch, W.1, Grommisch, L.1, Al-Ali, H.1, Storer, B.2,3,
Maloney, D.2,3, Petersdorf, E.2,3, McSweeney, P.9, Chauncey, T.2,3,10,
Agura, E.11, Epner, E.12, Maziarz, R.T.13, Petersen, F.14, Bruno, B.15,
Storb, R.2,3 1University of Leipzig, Leipzig, Germany; 2Fred Hutchin-
son Cancer Research Center, Seattle, WA; 3University of Washington,
Seattle, WA; 4Stanford University, Palo Alto, CA; 5Bone Marrow
Transplant Unit, Medical University of Vienna, Vienna, Austria; 6Ho-
pital Henri Mondor, Creteil, France; 7Hotel Dieu, Paris, France; 8Uni-
versity Hospital, Bale, Switzerland; 9University of Colorado, Denver,
CO; 10Seattle Veterans Administration Medical Center, Seattle, WA;
11Baylor University, Dallas, TX; 12University of Arizona, Tucson, AR;
13Oregon Health & Science University, Portland, OR; 14University of
Utah, Salt Lake City, UT; 15University of Torino, Torino, Italy.
Conventional allogeneic hematopoietic cell transplantation
(HCT) is an effective treatment for patients with acute myeloge-
nous leukemia (AML), but its use is restricted to younger individ-
uals in good medical condition. The use of low-dose irradiation
based preparative regimens has allowed the extension of allograft-
ing to older and medically inﬁrm patients. The present study
included 122 patients, 117 of whom were ineligible for conven-
tional HCT. Their disease stages ranged from complete remission
(CR1) to resistant AML. Patients were conditioned with 200 cGy
TBI on day 0 with or without preceding ﬂudarabine (30 mg/m2/
day from days 4 to 2), and given postgrafting cyclosporine at
6.25 mg/kg twice daily from day 3 and mycophenolate mofetil at
15 mg/kg twice daily from day 0. Human leukocyte antigen (HLA)
matched related donors were used in 58 and HLA matched/par-
tially mismatched unrelated donors in 64 patients. Among the
121 evaluable patients, 117 (96.7%) had durable hematopoietic
engraftment. Cumulative incidences of acute graft-versus-host
disease (GvHD) grades II-IV at 6 months were 33% after
related and 42% after unrelated HCT, respectively. With a
median follow up of 17 months (range 4-57), 58 patients were
alive, 53 of whom were in complete remission. Cumulative
non-relapse mortalities were 12% and 27%, and cumulative
mortalities from disease progression were 46% and 34% at 2
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